imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agenti antineoplastici - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
tosuman berna
istituto sieroterapico e vaccinogeno svizzero berna - immunoglobulina umana antipertussica - immunoglobulina umana antipertussica
tetuman berna
crucell italy s.r.l. - immunoglobulina tetanica - immunoglobulina tetanica
immunotetan
kedrion s.p.a. - immunoglobulina tetanica - immunoglobulina tetanica
rhesuman berna
crucell italy s.r.l. - immunoglobulina anti-d (rh) - immunoglobulina anti-d (rh)
rhesogamma
csl behring gmbh - immunoglobulina anti-d (rh) - immunoglobulina anti-d (rh)
tetagamma
hardis s.p.a. - immunoglobulina tetanica - immunoglobulina tetanica
morbilgamma
farma biagini spa - immunoglobulina anti-epatite b - immunoglobulina anti-epatite b
pertus gamma
farma biagini spa - immunoglobulina umana antipertussica - immunoglobulina umana antipertussica
pargamma
farma biagini spa - immunoglobulina umana antiparotitica - immunoglobulina umana antiparotitica